ADITXT INC. Aktie

Aditxt has named Jeff Busch CEO of its recently acquired subsidiary Ignite Proteomics. Busch will lead the commercial expansion and evaluate strategic growth and financing options to achieve sustainable profitability. Ignite operates a commercial precision oncology platform whose tests are reimbursed by Medicare. » More on de.investing.com

Aditxt has acquired Ignite Proteomics for a nominal $36 million, issuing 36,000 newly created convertible series A-2 preferred shares; Ignite will be integrated as a subsidiary into Aditxt’s oncology initiatives. Ignite operates a CLIA- and CAP-accredited laboratory, uses a reverse-phase protein array platform to measure functional protein biomarkers, and has established a Medicare reimbursement pathway of about $2,200 per test. The company plans a 2026 program covering more than 600,000 patients with metastatic cancer and estimates the addressable market potential at roughly $3 billion; it collaborates with partners including Inova Health, Dana-Farber and Vanderbilt. The acquisition comes despite Aditxt’s significant financial weakness (market capitalization ~ $640,000, deeply negative margins and high share-price volatility). » More on de.investing.com

Aditxt will implement a 1-for-8 reverse stock split at the opening of trading on March 9; fractional shares will be rounded up. After the split, the number of issued and outstanding common shares will be reduced to about 517,856, and the CUSIP will change to 007025877. Options and warrants will be adjusted proportionally; the split aims to meet NASDAQ minimum bid price requirements. The stock trades near its 52-week low and the company has a small market capitalization of roughly $840,000. » More on de.investing.com